Kyongbo Pharmaceutical Co., Ltd. (214390) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Kyongbo Pharmaceutical Co., Ltd. (214390:KRX), powered by AI.

Current Price
₩6,770
P/E Ratio
34.9
Market Cap
161.8B
Sector
Healthcare
What is the Kyongbo Pharmaceutical Co., Ltd. stock price forecast?

Kyongbo Pharmaceutical Co., Ltd. is currently trading at ₩6,770. View real-time AI analysis on Alpha Lenz.

What is Kyongbo Pharmaceutical Co., Ltd. insider trading activity?

View the latest insider trading data for Kyongbo Pharmaceutical Co., Ltd. on Alpha Lenz.

What is Kyongbo Pharmaceutical Co., Ltd.'s P/E ratio?

Kyongbo Pharmaceutical Co., Ltd.'s P/E ratio is 34.9.

Kyongbo Pharmaceutical Co., Ltd.

KRX · 214390
₩6,770
Ask about Kyongbo Pharmaceutical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Kyongbo Pharmaceutical Co., Ltd. trades at a P/E of 34.9 (premium valuation) with modest ROE of 3.2%. 3Y revenue CAGR of 11.8% highlights clear growth momentum.

Ask for details

Company Overview

Kyongbo Pharmaceutical Co., Ltd. is a prominent pharmaceutical company engaged in the research, development, and manufacture of medical products. Its primary function is to create and supply a wide range of pharmaceutical solutions, aiming to enhance human health and well-being. The company specializes in producing a variety of medications, including antibiotics, cardiovascular drugs, and gastroenterological products, reflecting its commitment to addressing diverse medical needs. Kyongbo Pharmaceutical Co., Ltd. plays a significant role in the healthcare sector, impacting both domestic and international markets with its high-quality pharmaceutical offerings. Founded with a mission to improve healthcare outcomes, it continuously invests in innovation and clinical research to ensure the efficacy and safety of its products. As a key player in the pharmaceutical industry, Kyongbo Pharmaceutical Co., Ltd. contributes to the availability of essential medicines, supporting the global healthcare infrastructure and helping meet the rising demand for effective health solutions.

CEO김태영
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
0

Company Statistics

FY 2024

Profile

₩161,849,442,200Market Cap
₩238,556,125,920Revenue
23.91MShares Out
0Employees

Margins

34.55%Gross
9.15%EBITDA
4.38%Operating
2.06%Pre-Tax
1.94%Net

Valuation

34.89P/E
1.11P/B
0.68EV/Sales
11.42EV/EBITDA
-12.43P/FCF

Growth (CAGR)

11.81%Rev 3Yr
4.47%Rev 5Yr
N/AOp Inc 3Yr
11.03%Op Inc 5Yr
N/ANet Inc 3Yr
-2.57%Net Inc 5Yr

Returns

1.69%ROA
3.19%ROE
3.34%ROIC

Financial Health

₩4,127,750,050Cash & Cash Equivalents
₩133,604,884,060Net Debt
94.24%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Kyongbo Pharmaceutical Co., Ltd. (ticker: 214390) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $161.8B.

The current price is ₩6,770 with a P/E ratio of 34.89x and P/B of 1.11x.

ROE is 3.19% and operating margin is 4.38%. Annual revenue is $238.6B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Kyongbo Pharmaceutical Co., Ltd. (Healthcare) Stock Forecast & Analysis ₩6,770 | Alpha Lenz